Bone events and evolution of biologic markers in Gaucher disease before and during treatment
Open Access
- 1 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 12 (4), R156
- https://doi.org/10.1186/ar3111
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Type 2 Gaucher disease: 15 new cases and review of the literatureBrain & Development, 2006
- Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher diseaseBlood Cells, Molecules, and Diseases, 2005
- Recent clinical progress in Gaucher diseaseCurrent Opinion in Pediatrics, 2005
- Molecular and cell biology of acid β-glucosidase and prosaposinProgress in Nucleic Acid Research and Molecular Biology, 2000
- Gaucher DiseaseArchives of Internal Medicine, 1999
- 5 Neuronopathic forms of Gaucher's diseaseBailliere's Clinical Haematology, 1997
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.JCI Insight, 1994
- Immunochemical Characterization of Two Activator Proteins Stimulating Enzymic Sphingomyelin Degradation in vitro Absence of One of them in a Human Gaucher Disease VariantBiological Chemistry Hoppe-Seyler, 1986
- Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's diseaseBiochemical and Biophysical Research Communications, 1965